Loading…

Intermittent body composition analysis as monitoring tool for muscle wasting in critically ill COVID-19 patients

Objectives SARS-CoV-2 virus infection can lead to acute respiratory distress syndrome (ARDS), which can be complicated by severe muscle wasting. Until now, data on muscle loss of critically ill COVID-19 patients are limited, while computed tomography (CT) scans for clinical follow-up are available....

Full description

Saved in:
Bibliographic Details
Published in:Annals of intensive care 2023-07, Vol.13 (1), p.61-61, Article 61
Main Authors: Kolck, Johannes, Rako, Zvonimir A., Beetz, Nick L., Auer, Timo A., Segger, Laura K., Pille, Christian, Penzkofer, Tobias, Fehrenbach, Uli, Geisel, Dominik
Format: Article
Language:English
Subjects:
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Objectives SARS-CoV-2 virus infection can lead to acute respiratory distress syndrome (ARDS), which can be complicated by severe muscle wasting. Until now, data on muscle loss of critically ill COVID-19 patients are limited, while computed tomography (CT) scans for clinical follow-up are available. We sought to investigate the parameters of muscle wasting in these patients by being the first to test the clinical application of body composition analysis (BCA) as an intermittent monitoring tool. Materials BCA was conducted on 54 patients, with a minimum of three measurements taken during hospitalization, totaling 239 assessments. Changes in psoas- (PMA) and total abdominal muscle area (TAMA) were assessed by linear mixed model analysis. PMA was calculated as relative muscle loss per day for the entire monitoring period, as well as for the interval between each consecutive scan. Cox regression was applied to analyze associations with survival. Receiver operating characteristic (ROC) analysis and Youden index were used to define a decay cut-off. Results Intermittent BCA revealed significantly higher long-term PMA loss rates of 2.62% (vs. 1.16%, p  
ISSN:2110-5820
2110-5820
DOI:10.1186/s13613-023-01162-5